Venture Capital

Horn & Co. advises companies, founders, government funded incubators, private investors and venture capital funds with respect to their full range of finance transactions. The firm’s close acquaintance with both company and investor needs and limitations enables it to provide a unique view and expertise to transactions. Our close acquaintance with both company and investor needs and limitations enables us to provide a unique view and expertise to transactions. We have been involved in the formation of venture capital funds (including Pontifax II (2007), Pontifax III (2011) and Pontifax 4 (2015), and regularly advise such funds with respect to their relationships with their limited partners. We represent funds in their investments in new companies and monitoring of their agreements with previous investments. The members of Horn & Co. have represented investors in funds, in private rounds of finance of companies, in PIPEs and in protecting their interests in mergers of portfolio companies.
The firm represents dozens of technology, venture capital backed companies, in their ongoing corporate and commercial lifecycles. Recent examples of funding of such representation include: o Representation of Taboola.com in a Series E financing round of more than $ 120 million (2014-2015).
o Representation of Biolight Israeli Life Sciences Investments Ltd (TASE: BOLT) in the entering into a memorandum for strategic cooperation in China and closing of a $6.6 million investment with investors based in Hong Kong (2015).
o Representation of a consortium of foreign and local investment funds in a private financing of up to $ 10 million, in a medical devices company (2015).
o Representation of a US investment fund in a private financing of up to $ 5 million, in a medical devices company (2014).
o Protalix BioTherapeutics Inc. in a purchase agreement with Citigroup Capital Markets Inc. for the sale by the Company of $60 million aggregate principal amount of Convertible Notes, in a private placement to “qualified institutional buyers” in the United States, under the Securities Act of 1933 (2013).
o SEB Alliance SAS in its investment in Advanced MemTech Ltd., an Israeli private company (2013).
o Restructuring of capitalization and $16 Million investment.
o Pontifax Funds, the leading Israeli life sciences VC funds, in dozens of investments (2007- today).
o Private funding of $12 million in a company in the cardiology field (2011);
o Drug development company in its $20 million private funding (2010);
o The distribution by a fund of its publicly traded shares (October 2009);
o The seed funding of several incubator companies (2010);
o Distressed funding of a medical device company (2010);
o Private and planned public funding of a drug development company;
o Private transactions preceding a public offering of a drug development company.